A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Study to Evaluate the Efficacy and Safety of ViphyllinTM on Brain Health and Cognitive function in Healthy Subjects.

Vidya Herbs Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年6月27日

试验速览

暂无简介。

•1. Subjects with a MMSE Score >= 23
•2. Diabetes, hypertension and other medical condition patients should be on stable medication for last 3 months
•3. Should not be an any medication for cognition and other neurological disorders
•4. Females of childbearing age, agree to use approved birth control methods during the study, and have negative urine pregnancy test (UPT) at screening
•5. Non-smokers
•6. Able to communicate verbally, able to write and speak English and comfortable with using computer
•7. Must be willing and able to give informed consent and comply with the study procedures.

•1. Subjects with history of
•-Respiratory bacterial or viral infection (including COVID-19) in the past 2 weeks
•- Psychiatric disorders
•- Severe neurological diseases or seizures
•- Uncontrolled / serious medical illness including diabetes, liver disease, hypertension
•- Cardiac Disease/Neurological Problems/
•- Auto-immune disease (rheumatoid arthritis, lupus, type 1 diabetes)
•-Gastrointestinal tract bleeding / peptic ulcer disease
•2. Subjects who maybe allergic to any of the natural constituents of the Investigational Product.
•3. Known HIV or Hepatitis B positive or any other immuno-compromised state
•4. Subjects on any other medical or clinical investigation or on any nutrition supplements and dietary regime.
•5. Subjects visually or mentally handicapped or having difficulty to communicate
•6. History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol.
•7. Currently participating or having participated in another clinical trial during the last 3 months prior to the beginning of this study.

发起方